Your browser doesn't support javascript.
loading
Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia.
Li, Yilong; Schwab, Claire; Ryan, Sarra; Papaemmanuil, Elli; Robinson, Hazel M; Jacobs, Patricia; Moorman, Anthony V; Dyer, Sara; Borrow, Julian; Griffiths, Mike; Heerema, Nyla A; Carroll, Andrew J; Talley, Polly; Bown, Nick; Telford, Nick; Ross, Fiona M; Gaunt, Lorraine; McNally, Richard J Q; Young, Bryan D; Sinclair, Paul; Rand, Vikki; Teixeira, Manuel R; Joseph, Olivia; Robinson, Ben; Maddison, Mark; Dastugue, Nicole; Vandenberghe, Peter; Stephens, Philip J; Cheng, Jiqiu; Van Loo, Peter; Stratton, Michael R; Campbell, Peter J; Harrison, Christine J.
Afiliação
  • Li Y; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Schwab C; Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Ryan S; Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Papaemmanuil E; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Robinson HM; West Midlands Regional Genetics Laboratory, Birmingham Women's NHS Foundation Trust, Birmingham, UK.
  • Jacobs P; Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK.
  • Moorman AV; Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Dyer S; West Midlands Regional Genetics Laboratory, Birmingham Women's NHS Foundation Trust, Birmingham, UK.
  • Borrow J; School of Cancer Sciences, University of Birmingham, Birmingham, UK.
  • Griffiths M; West Midlands Regional Genetics Laboratory, Birmingham Women's NHS Foundation Trust, Birmingham, UK.
  • Heerema NA; School of Cancer Sciences, University of Birmingham, Birmingham, UK.
  • Carroll AJ; West Midlands Regional Genetics Laboratory, Birmingham Women's NHS Foundation Trust, Birmingham, UK.
  • Talley P; School of Cancer Sciences, University of Birmingham, Birmingham, UK.
  • Bown N; Department of Pathology, The Ohio State University, Columbus, OH.
  • Telford N; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL.
  • Ross FM; Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK.
  • Gaunt L; Cytogenetics Laboratory, Northern Genetics Service, Newcastle upon Tyne, UK.
  • McNally RJQ; Oncology Cytogenetics, The Christie NHS Foundation Trust, Manchester, UK.
  • Young BD; Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK.
  • Sinclair P; Regional Cytogenetics Unit, Genetic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Saint Mary's Hospital, Manchester, UK.
  • Rand V; Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.
  • Teixeira MR; Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Joseph O; Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Robinson B; Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Maddison M; Genetics Department, Portuguese Oncology Institute, and Biomedical Sciences Institute (ICBAS), Porto University, Portugal.
  • Dastugue N; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Vandenberghe P; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Stephens PJ; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Cheng J; Laboratoire d'hématologie, Génétique des Hémopathies, Hôpital Purpan, Toulouse, France.
  • Van Loo P; Center for Human Genetics, University Hospital Leuven and KU Leuven, Leuven, Belgium.
  • Stratton MR; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Campbell PJ; Center for Human Genetics, University Hospital Leuven and KU Leuven, Leuven, Belgium.
  • Harrison CJ; Department of Electrical Engineering - ESAT, University of Leuven, Leuven, Belgium.
Nature ; 508(7494): 98-102, 2014 Apr 03.
Article em En | MEDLINE | ID: mdl-24670643
ABSTRACT
Changes in gene dosage are a major driver of cancer, known to be caused by a finite, but increasingly well annotated, repertoire of mutational mechanisms. This can potentially generate correlated copy-number alterations across hundreds of linked genes, as exemplified by the 2% of childhood acute lymphoblastic leukaemia (ALL) with recurrent amplification of megabase regions of chromosome 21 (iAMP21). We used genomic, cytogenetic and transcriptional analysis, coupled with novel bioinformatic approaches, to reconstruct the evolution of iAMP21 ALL. Here we show that individuals born with the rare constitutional Robertsonian translocation between chromosomes 15 and 21, rob(15;21)(q10;q10)c, have approximately 2,700-fold increased risk of developing iAMP21 ALL compared to the general population. In such cases, amplification is initiated by a chromothripsis event involving both sister chromatids of the Robertsonian chromosome, a novel mechanism for cancer predisposition. In sporadic iAMP21, breakage-fusion-bridge cycles are typically the initiating event, often followed by chromothripsis. In both sporadic and rob(15;21)c-associated iAMP21, the final stages frequently involve duplications of the entire abnormal chromosome. The end-product is a derivative of chromosome 21 or the rob(15;21)c chromosome with gene dosage optimized for leukaemic potential, showing constrained copy-number levels over multiple linked genes. Thus, dicentric chromosomes may be an important precipitant of chromothripsis, as we show rob(15;21)c to be constitutionally dicentric and breakage-fusion-bridge cycles generate dicentric chromosomes somatically. Furthermore, our data illustrate that several cancer-specific mutational processes, applied sequentially, can coordinate to fashion copy-number profiles over large genomic scales, incrementally refining the fitness benefits of aggregated gene dosage changes.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromossomos Humanos Par 21 / Aberrações Cromossômicas / Leucemia-Linfoma Linfoblástico de Células Precursoras Limite: Humans Idioma: En Revista: Nature Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromossomos Humanos Par 21 / Aberrações Cromossômicas / Leucemia-Linfoma Linfoblástico de Células Precursoras Limite: Humans Idioma: En Revista: Nature Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Reino Unido